Search results
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Zacks via Yahoo Finance· 7 hours agoKeytruda development program is also progressing well. The drug is being studied for more than 30...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga· 1 day agoThe trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab)...
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Zacks via Yahoo Finance· 1 day agoBristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails...
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise
MedPage Today· 5 days agoNews, features, and commentary about cancer-related issues
ImmunityBio Advances On the Anktiva Front
Los Angeles Business Journal· 2 days agoImmunityBio Inc., the Culver City-based immunotherapy company founded by billionaire Patrick Soon-Shiong that last month won Food and Drug Administration approval for its ...
2 No-Brainer Dividend Stocks to Buy in May
Motley Fool via Yahoo Finance· 5 days agoThe oncology market is known for its strong pricing power, with cancer drugs typically carrying high price tags and significant margins. While Pfizer's...
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Zacks via Yahoo Finance· 4 days agoIovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for...
Is Johnson & Johnson Stock A Better Pick Over Merck?
Forbes· 15 hours agoAlthough Merck trades at a higher valuation of 5.5x trailing revenues, compared to 4.2x for J&J, we think that this valuation gap will likely narrow over...
Is Eli Lilly Stock A Better Pick Over Amgen?
Forbes· 2 days agoAlso, Eli Lilly has seen a better revenue growth and is more profitable. There is more to the comparison, and in the sections below, we discuss why we...
Merck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.
Quartz· 6 days agoEvery pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar ...
